# US 2023/0055468 A1 · Broadly reactive viral antigens as immunogens, compositions and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0055468 A1
- Document ID: US20230055468A1
- Status: Published application
- Kind: A1
- Application number: 17/791,861
- Filed: 2021-01-08
- Published: 2023-02-23
- Earliest claimed: 2020-01-10
- Assignees: University of Georgia Research Foundation, Inc.
- Applicants: University of Georgia Research Foundation, Inc.
- Inventors: James ALLEN; Zachary Beau RENEER; Ivette NUNEZ; Hyesun JANG; Michael CARLOCK; Ted ROSS
- Web page: https://patentgrep.com/patent/US20230055468A1

## CPC

- A61K 39/12: Viral antigens
- A61K 39/145: Orthomyxoviridae, e.g. influenza virus
- A61P 31/16: for influenza or rhinoviruses
- C12N 15/09: Recombinant DNA-technology
- C12N 2760/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided herein are non-naturally occurring, broadly reactive antigens derived from influenza viruses or avian infectious bronchitis virus (IBV) that are immunogenic and capable of eliciting a broadly reactive immune response, e.g., a broadly reactive neutralizing antibody response, directed against influenza virus antigens or IBV antigens following introduction into a subject. Also provided are non-naturally, broadly reactive immunogens, vaccines, virus-like particles (VLPs) and compositions comprising the immunogens and vaccines. Methods of generating an immune response in a human or non-human subject by administering the immunogens, vaccines, VLPs, or compositions thereof are provided. In particular, the immunogens comprise broadly reactive hemagglutinin (HA) protein antigens of influenza virus strains, such as H1, H2, H3, H5, or H7, or of IBV. The immunogens also comprise broadly reactive viral neuraminidase (NA) protein antigens.

## Claims

### Claim 1

A non-naturally occurring and immunogenic influenza virus antigen, comprising an amino acid sequence that is at least 95% identical to an amino acid sequence of a hemagglutinin (HA) antigen as set forth in FIGS. 1A-1E, or an antigen binding portion thereof.

### Claim 2 (depends on 1)

The influenza virus antigen of claim 1, which comprises an amino acid sequence that is at least 98% identical to an amino acid sequence of an HA antigen as set forth in FIGS. 1A-1E.

### Claim at position 3

3-4. (canceled)

### Claim 5 (depends on 1)

The influenza virus antigen of claim 1, wherein the influenza virus is an H1, H2, H3, H5, or H7 influenza virus.

### Claim 6

A non-naturally occurring and immunogenic influenza virus antigen, comprising or consisting of an amino acid sequence that is at least 95% identical to an amino acid sequence of a neuraminidase (NA) antigen as set forth in FIGS. 2A and 2B, or an antigen binding portion thereof.

### Claim at position 6

7-9. (canceled)

### Claim 10 (depends on 6)

The influenza virus antigen of claim 6, wherein the influenza virus is an H1, H2, H3, H5, or H7 influenza virus.

### Claim 11

A non-naturally occurring and immunogenic avian infectious bronchitis virus (IBV) antigen, comprising or consisting of an amino acid sequence that is at least 95% identical to an amino acid sequence of a hemagglutinin (HA) antigen as set forth in FIG. 1F, or an antigen binding portion thereof.

### Claim at position 9

12-14. (canceled)

### Claim 15 (depends on 1)

A virus-like particle (VLP) comprising the virus antigen of claim 1.

### Claim 16 (depends on 15)

The VLP of claim 15, which comprises a polynucleotide encoding the influenza virus HA or NA antigen.

### Claim 17

(canceled)

### Claim 18

A non-naturally occurring immunogen capable of generating an immune response against present and future influenza virus strains; wherein the immunogen comprises an amino acid sequence that is at least 95% identical to an amino acid sequence of a hemagglutinin (HA) antigen as set forth in FIGS. 1A-1E, and/or wherein the immunogen comprises an amino acid sequence that is at least 95% identical to an amino acid sequence of a neuraminidase (NA) antigen as set forth in FIGS. 2A and 2B.

### Claim 19

(canceled)

### Claim 20

A non-naturally occurring immunogen capable of generating an immune response against present and future avian infectious bronchitis virus (IBV) strains; wherein the immunogen comprises an amino acid sequence that is at least 95% identical to an amino acid sequence of hemagglutinin (HA) antigen as set forth in FIG. 1F.

### Claim 21

(canceled)

### Claim 22 (depends on 1)

The virus antigen, VLP, or immunogen of claim 1, wherein the immune response comprises the production of neutralizing antibodies.

### Claim 23 (depends on 1)

The virus antigen, VLP, or immunogen of claim 1, wherein the immune response comprises the production of antibodies having hemagglutinin inhibitory activity and/or neuraminidase inhibitory activity.

### Claim 24

(canceled)

### Claim 25 (depends on 1)

A pharmaceutically acceptable composition comprising the virus antigen, VLP, or immunogen of claim 1 and a pharmaceutically acceptable carrier, diluent, or excipient.

### Claim 26

(canceled)

### Claim 27 (depends on 1)

An immunogenic composition or vaccine comprising the virus antigen, VLP, immunogen of claim 1.

### Claim 28 (depends on 27)

A pharmaceutically acceptable composition comprising the immunogenic composition or vaccine of claim 27 and a pharmaceutically acceptable carrier, diluent, or excipient.

### Claim 29

(canceled)

### Claim 30 (depends on 1, 25, 27)

A method of generating an immune response in a subject, the method comprising administering to the subject an effective amount of the virus antigen, VLP, or immunogen of claim 1, the pharmaceutical composition of claim 25, or the immunogenic composition or vaccine of claim 27.

### Claim at position 26

31-36. (canceled)

### Claim 37 (depends on 30)

The method of claim 30, wherein the subject is a human subject.

### Claim 38

(canceled)

### Claim 39 (depends on 1)

A polynucleotide encoding the virus antigen of claim 1.

### Claim 40 (depends on 39)

A composition comprising the polynucleotide of claim 39 and a pharmaceutically acceptable carrier, diluent, or excipient.

### Claim 41 (depends on 39)

A virus-like particle (VLP) comprising the polynucleotide of claim 39.
